In Vitro Diagnostics Business Outlook, Volume 3, Issue 5 - Point-of-Care (POC)
In Vitro Diagnostics Business Outlook offers information and data that you cannot get anywhere else, including:
Market data and forecasts (growth rates, market size, market share, etc.) to identify growth opportunities
- A comprehensive view of the IVD market with test categories covered and company briefs
- M&A activities, selected partnerships & collaborations, partnership deals, and more
- Industry & region watch to help tailor strategies
- Analysis of news and events and reporting on news not easily available
- MARKET ANALYSIS: IVD POC TESTING
- OVERVIEW OF IVD POC TESTING
- MARKET OUTLOOK
- Table: Global POC Diagnostic Market, by Broad Segment, 2024 and 2029 ($ million) (professional testing, self-testing)
- Figure: Point-of-Care Diagnostics (COVID-19 vs. non-COVID testing), 2020-2024 ($ million)
- Figure: Global POC Diagnostic Market Distribution, by Segment, 2024 (%) (Cardiac Care; Coagulation; Critical Care; Drug of Abuse; Fecal Occult Blood; Glucose; Hematology; Infectious Disease Lipid [Cholesterol]; Pregnancy/Fertility; Urinalysis; Others)
- Selected Product Activity
- REGIONAL MARKET
- Figure: POC Diagnostics Market Value, by Global Region, 2024 ($ million) (North America, Europe, Asia Pacific, Latin America, Middle East, Africa)
- COMPANY BRIEFS
- Abbott Diagnostics
- Dexcom
- Roche
- EXECUTIVE NEWS BRIEFING
- BRIEFS
- Quanterix Appoints New Member to Board of Directors
- Beckman Coulter Appoints New President
- MARAbio Raises $19 Million in Series A Funding
- Amprion Makes Advances in Series B Financing
- Sunbird Bio Closes $14 Million Financing Round
- Bruker Reported 17% Growth in Second Quarter 2024 and 11% Growth for the First Six Months
- Figure: Bruker Corporation Sales, by Business, H1 2023 Compared to H1 2024 (Bruker BioSpin, Bruker CALID, Bruker Nano, BEST, Eliminations)
- Figure: Bruker CALID Quarterly Performance, Sales by Quarter, Q1 2022 - Q2 2024
- Figure: Bruker Corporation H1 2023 and H1 2024 Regional Sales Breakdown Distribution (Asia Pacific, Japan; Europe; United States; Other)
- Myriad Genetics Reports 13% Revenue Growth in First Half 2024
- Table: Myriad Genetics Revenue Mix, by Product, H1 2023 vs H1 2024 ($ million) (Hereditary Cancer; Pharmacogenomics; Prenatal; Tumor Profiling)
- Figure: Myriad Genetics Revenue Mix, by Business Unit, Quarterly Performance Q1 2023 through Q2 2024 ($ million) (Mental Health, Oncology, Women’s Health)
- DIAGNOSTIC MARKET MERGERS, ACQUISITIONS AND PARTNERSHIP DEALS
- PARTNERSHIPS AND COLLABORATIONS
- MERGERS AND ACQUISITIONS
- Table: Recent Diagnostic Market Mergers, Acquisitions and Partnership Deals
- INDUSTRY WATCH
- INDUSTRY WATCH COVID-19/FLU UPDATE
- REGION WATCH
- FINLAND
- Figure: Finland GDP Value and Growth, by Year, 2013-2023 ($ billion)
- Figure: Finland Social Protection Expenditure by Function, 1995-2022 in 2022 Prices (€ billion)
- Figure: Finland IVD Market, 2019-2024 ($ million)
- BROAD-BASED COMPANY ANNOUNCEMENTS
- ANNOUNCEMENTS
- Roche Launches TAGS Technology Test
- Exact Sciences Welcomes New Cologuard Plus Test
- PreAnalytiX Launches PAXgene Urine Liquid Biopsy Set
- Abionic Launches Early Sepsis Test
- QIAGEN Expands Liquid Biopsy Portfolio
- FoundationOne Gains Liquid CDx Approval
- Revvity’s Euroimmun Announces Groundbreaking Launch in the EU
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook